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EDITORIAL
Prothymosin alpha as a cystogen
Prothymosin alpha is not a protein of focus to renal re-
searchers. Prothymosin a (ProT) is one of a group of pro-
teins that was initially isolated from thymus in a search
for factors that control thymic function. None of these ini-
tial thymosins were actually thymic hormones, but were
found to have diverse functions in many tissues and cells
[1]. In the present issue of Kidney International, Li et al
[2] describe polycystic kidneys in mice that express a ProT
transgene driven by a b-actin promoter. In addition, ProT
overexpression was found in human autosomal-dominant
(AD) and autosomal-recessive (AR) polycystic kidneys,
suggesting that ProT overexpression is a general feature
of various inherited forms of cystic renal disease. In a mi-
croarray study of autosomal-dominant polycystic kidney
disease (ADPKD) cells, prothymosin does not appear to
be one of the overexpressed mRNAs [3]; however, the
overexpression of prothymosin a, and its capability to
cause cystic transformation, is clearly evident from the
article in this issue. The association of prothymosin a with
polycystic kidney disease (PKD) appears to be related to
its role in cell proliferation and neoplasia. Some consider
prothymosin alpha to be an oncoprotein [4]. Prothymosin
a has been closely linked to malignant neoplasia in lung,
liver, breast, and stomach. Increased cell proliferation is
a central feature of cystic renal disease as well, leading
Grantham to describe PKD as “neoplasia in disguise”
[5]. ProT expression appears to correlate with the ag-
gressiveness of some cancers [6, 7]. Li et al [2] suggest the
possibility that ProT in urine might be useful in diagnos-
ing or predicting the aggressiveness of PKD in ARPKD
and ADPKD similar to the dramatic increase of ProT in
the urine of prothymosin a mice.
Another oncogene, c-myc, is also associated with cys-
tic epithelia in multiple forms of renal cystic disease.
Myc oncogenes are known to activate transcription of
the prothymosin gene, so an overexpression of ProT in
PKD may not have been unexpected. ProT is localized to
the nucleus of cells and is known to interact with cell-
cycle regulatory proteins [8], demonstrating one path-
way in which prothymosin could affect cell prolifera-
tion. Another potential pathway is through the EGF
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receptor, which Li et al [2] demonstrate is overexpressed
in the prothymosin a transgenic mice. EGF receptor
overexpression has been demonstrated in multiple mod-
els and human forms of PKD, and has been implicated
in the progression of the cystic disease in both kidney
and liver. Prothymosin can also associate with alpha-
tubulin and the mitotic spindle of dividing cells [9]. Mi-
crotubules were implicated in PKD progression by the
studies of Woo [10], which showed that taxol can in-
hibit PKD progression in the cpk, and many of the PKD
gene products are associated with microtubules (includ-
ing, but not limited to, polycystin 2, inversin, nephrocystin
4, some of the Bardt-Biedl syndrome proteins). There-
fore, ProT and PKD share a possible pathway involving
microtubules/cilia. Polycystin 2, the protein product of
the PKD2 gene, is a calcium channel, and reduced cal-
cium has been shown to play a role in the pathogenesis
of ADPKD. Prothymosin has calcium-binding properties
[11] that may exacerbate the problem of low cellular cal-
cium in cystic epithelia, possibly contributing to the cys-
togenic action of ProT in these transgenic mice. Other
recent data suggest that cAMP generated by overactivity
of vasopressin V2 receptor contributes to the progression
of various forms of PKD [12, 13]. Cyclic AMP also in-
fluences gene transcription at cAMP response elements
(CRE) via cyclic AMP response element-binding pro-
teins (CREB), and ProT directly interacts with CREB
[14]. Therefore, ProT has the capability to influence gene
transcription in the cAMP/CREB pathway known to in-
fluence PKD progression.
Prothymosin a can interact directly with several path-
ways known to be involved in the pathogenesis and pro-
gression of PKD. While a few mutated gene loci are
known to initiate PKD (i.e., PKD1, PKD2, PKHD1, etc.),
there may be a wide variety of genes/gene products like
ProT that contribute to the progression of cystic change.
Prothymosin a has emerged as a potentially important
contributor to PKD progression, making it a new target
for future studies.
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